- $680.63m
- $658.47m
Brief: Nuvectis Pharma Provides Final Clinical Data Update From The NXP800 Phase 1B Study In Ovarian Cancer And Reports Completion Of The NXP900 Phase 1A Dose Escalation Study
Brief: Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment In Phase 1B Study In Patients With Platinum-Resistant Arid1a-Mutated Ovarian Cancer
Brief: Nuvectis Pharma Q3 Net Income USD -4.153 Million
Brief: Nuvectis Pharma Announces Orphan Drug Designation Granted By The FDA For Nxp800
Brief: Nuvectis Pharma Q2 Net Income USD -4.428 Million
Nuvectis Pharma Inc expected to post a loss of 26 cents a share - Earnings Preview
Nuvectis Pharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: Nuvectis Pharma Q1 Net Income USD -4.171 Million
Nuvectis Pharma Inc expected to post a loss of 40 cents a share - Earnings Preview
Brief: Nuvectis Pharma's NXP900 Demonstrates Robust Activity In Non-Small Cell Lung Cancer Cell Lines
Nuvectis Pharma Inc reports results for the quarter ended in December - Earnings Summary
Nuvectis Pharma Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Nuvectis Pharma Q3 Net Income USD -5.881 Million
Nuvectis Pharma Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Nuvectis Pharma Announces Initiation Of The NXP900 Phase 1A Clinical Trial
Brief: Nuvectis Pharma Announces Initiation Of NXP900 Phase 1a Clinical Trial
U.S. STOCKS ON THE MOVE-Canopy Growth, Teck Resources, Chegg
U.S. STOCKS ON THE MOVE-Copper miners, US energy firms, CVS Health
Nuvectis Pharma up after FDA grants orphan drug tag to cancer treatment